|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Peginterferon al- fa-2b or alfa-2a with ribavirin for treatment of hepatitis C infec- tion显示文摘 | McHutchison JG Lawitz E J Shiffman ML | 2009 | N Engl J Med2009，361，6： | 1 |
| 2 | Peginter- feron alfa-2b or alfa -2a with ribavirin for treatment of hepati- tis C infection显示文摘 | McHutchison J G Lawitz E J Shiffman M L | 2009 | N Engl J Med2009，361，6： | 1 |
| 3 | Treatment of HCV infection by targeting microRNA显示文摘 | Janssen H L Reesink H W Lawitz E J Zeuzem S Ro- driguez-Torres M Patel K van der Meer A J Patick A K Chen A Zhou | 2013 | New England J Med2013，368，18： | 1 |
| 4 | A randomized, double-blind, placebo-controlled assessment of BMS:936558, a fully humanmonoclonal antibody to programmed death-1 (PD- 1 ), in patients with chronic hepatitis C virus infection 显示文摘 | Gardiner D Lalezari J Lawitz E | 2013 | PLoS One2013，8，63： | 1 |
| 5 | HCV SPRINT-1 final results: SVR 24 from a phase 2 study of boceprevir plus PeglFN alpha-2b/ribavirin in treatment-naive subjects with genotype 1 chronic hepatitis显示文摘 | Kwo P Lawitz E J McCone J | 2009 | J Hepatol2009，50，1： | 1 |
| 6 | Treatment of HCV infection by targeting microRNA 显示文摘 | Janssen HL Reesink HW Lawitz E J | 2013 | New England Journal of Medicine2013，368，18： | 1 |
| 7 | Short-term antiviral activity and safety of ACH-806 (GS-9132), an NS4A antagonist, in HCV genotype 1 infected individuals显示文摘 | Pottage J Lawitz E Mazur D | 2007 | J Hepatol2007，46，1： | 1 |
| 8 | Interferon-free, direct-acting antiviral therapy for chronic hepatitis C显示文摘 | GUTIERREZ JA LAWITZ E J POORDAD F | 2015 | Viral Hepat2015，2201，： | 1 |
| 9 | ACH-3102, a second generation NS5A inhibitor, demonstrates potent antiviral activity in patients with genotype 1a HCV infection despite the presence of baseline NS5A-resistant variants 显示文摘 | Muir A Hill J Lawitz E | 2013 | J Hepatol2013，58，1： | 1 |
| 10 | Peginterferon alfa -2b or alfa -2a with ribavirin for treatment of hepatitis C infection显示文摘 | McHutchison JG Lawitz E J Shiffman ML | 2009 | N Engl J Med2009，361，10： | 1 |
| 11 | HCV SPRINT-1 final results:SVR 24 from a phase 2 study of boceprevir plus Peglntron? (peginterferon alfa-2b)/ribavirin in treatment-naive subjects with genotype 1 chronic hepatitis C显示文摘 | Kwo P Lawitz E McCone J | | Journal of Hepatology0，，： | 1 |
| 12 | Interim results from HCV SPRINT-1:RVR/EVR from phase 2 study of boceprovir plus pegintron (peginteferon alfa-2b)/ribavirin in treatment-naive subjects with HCV genotype 1 CHC显示文摘 | Kwo P Lawitz E McCone J | 2008 | J Hepatol2008，48，2： | 1 |
| 13 | Treatment of HCV in- fection by targeting microRNA 显示文摘 | Janssen HL Reesink HW Lawitz E J | 2013 | N Engl J Med2013，368，18： | 1 |
| 14 | Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection显示文摘 | Mchutchison J G Lawitz E J Shiffman M L | 2009 | New Engl J Med2009，361，6： | 1 |
| 15 | Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non- cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial 显示文摘 | Lawitz E Lalezari J P Hassanein T | 2013 | Lancet Infect Dis2013，13，5： | 1 |
| 16 | Boceprevir for previously treated chronic HCV genotype 1 infection显示文摘 | Bacon B K Gordon S C Lawitz E Marcellin P Vierling J M Zeuzem S Poordad F Goodma | | 0，，13： | 1 |
| 17 | Peginterferon alfa -2b or alfa -2a with ribavirin for treatment of hepatitis C infection显示文摘 | McHutchison JG Lawitz E J Shiffman ML | 2009 | N Engl J Med2009，361，6： | 1 |
| 18 | Sofosbuvir in combination with peginterferon alfa-2a and ribavifin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomized, double-blind, phase 2 trial 显示文摘 | Lawitz E Lalezari J P Hassanein T | 2013 | LancetlnfectDis2013，13，5： | 1 |
| 19 | Peginterferon α -2b or α -2α with ribavirin for treatment of hepatitis C infection 显示文摘 | MeHutchison JG Lawitz E J Shiffman ML | 2009 | New Engl J Med2009，361，6： | 1 |
| 20 | Peginterferon atfa-2b or alfa-2a with fibavirin for treatment of hepatitis C infection 显示文摘 | McHutchison J G Lawitz E J Shiffman M L | 2009 | New England Journal of Medicine2009，361，6： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员